alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 516.145 Content and format of a request for addition to the index. ( a ) A requestor may request addition of a new animal drug to the index only after the new animal drug has been granted eligibility for indexing.
( b ) A requestor shall submit two copies of a dated request signed by the authorized contact for addition of a new animal drug to the index that contains the following: ( 1 ) A copy of FDA's determination of eligibility issued under § 516.137;
( 2 ) A copy of FDA's written determination that the proposed qualified expert panel meets the selection criteria provided for in § 516.141(b);
( 3 ) A written report that meets the requirements of § 516.143;
( 4 ) A proposed index entry that contains the information described in § 516.157;
( 5 ) Proposed labeling, including representative labeling proposed to be used for Type B and Type C medicated feeds if the drug is intended for use in the manufacture of medicated feeds;
( 6 ) Anticipated annual distribution of the new animal drug, in terms of the total quantity of active ingredient, after indexing;
( 7 ) A written commitment to manufacture the new animal drug and animal feeds bearing or containing such new animal drug according to current good manufacturing practices;
( 8 ) A written commitment to label, distribute, and promote the new animal drug only in accordance with the index entry;
( 9 ) The name and address of the contact person or permanent-resident U.S. agent; and
( 10 ) A draft Freedom of Information summary which includes the following information: ( i ) A general information section that contains the name and address of the requestor and a description of the drug, route of administration, indications, and recommended dosage.
( ii ) A list of the names and affiliations of the members of the qualified expert panel, not including their addresses or other contact information.
( iii ) A summary of the findings of the qualified expert panel concerning the target animal safety and effectiveness of the drug.
( iv ) Citations of all publicly-available literature considered by the qualified expert panel.
( v ) For an early life stage of a food-producing minor species animal, a human food safety summary.
( c ) Upon specific request by FDA, the requestor shall submit the information described in § 516.141 that it submitted to the qualified expert panel. Any such information not in English should be accompanied by an English translation.
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL  INFORMATION EXTACTED FROM THE GULFWEST
OIL COMPANY'S  QUARTELY REPORT FILED ON FORM 10-Q FOR THE QUARTE ENDED SEPTEMBER
30,  1998 AND IS  QUALIFIED  IN ITS  ENTIRETY  BY  REFERENCE  TO SUCH  FINANCIAL
STATEMENTS.
</LEGEND>
<CIK>                         0000813779
<NAME>                        0
<MULTIPLIER>                  1               
<CURRENCY>                    0                
       
<S>                            <C>
<PERIOD-TYPE>                  9-MOS
<FISCAL-YEAR-END>              DEC-31-1997                
<PERIOD-START>                 JUL-01-1998               
<PERIOD-END>                   SEP-30-1998                
<EXCHANGE-RATE>                1                
<CASH>                         0                
<SECURITIES>                   0               
<RECEIVABLES>                  756,297               
<ALLOWANCES>                   0                
<INVENTORY>                    0               
<CURRENT-ASSETS>               907,678               
<PP&E>                         25,626,293               
<DEPRECIATION>                 3,657,100               
<TOTAL-ASSETS>                 22,876,871               
<CURRENT-LIABILITIES>          14,113,422               
<BONDS>                        0                
<PREFERRED-MANDATORY>          0                
<PREFERRED>                    92                
<COMMON>                       2,963                
<OTHER-SE>                     3,085,583                
<TOTAL-LIABILITY-AND-EQUITY>   22,876,871                
<SALES>                        439,614               
<TOTAL-REVENUES>               628,192                
<CGS>                          0                
<TOTAL-COSTS>                  1,129,512                
<OTHER-EXPENSES>               0               
<LOSS-PROVISION>               0               
<INTEREST-EXPENSE>             (389,448)             
<INCOME-PRETAX>                (890,768)                
<INCOME-TAX>                   0              
<INCOME-CONTINUING>            (890,768)               
<DISCONTINUED>                 0                
<EXTRAORDINARY>                0                
<CHANGES>                      0              
<NET-INCOME>                   (890,768)               
<EPS-PRIMARY>                  (.32)                
<EPS-DILUTED>                  (.32)                
        

</TABLE>
----

| Name                                           |   | Jurisdiction     |
|------------------------------------------------|--------|------------------|
| Level      8 Technologies, Inc.                |   | Delaware         |
|                                           |   |             |
| Cicero      Technologies, Inc,                 |   | Delaware         |
|                                           |   |             |
| Cicero      Technologies Acquisition, LLC      |   | Delaware         |
|                                           |   |             |
| Template      Software de Mexico, S.A. de C.V. |   | Mexico           |
|                                           |   |             |
| Level      8 Systems Australia Pty Ltd         |   | Australia        |
|                                           |   |             |
| Template      Software Holding GmbH            |   | Germany          |
| Template      SoftwareGeschaftsfuhrungs GmbH   |   | Germany          |
| Template Software      GmbH                    |   | Germany          |
|                                           |   |             |
| Level      8 Worldwide Holdings Ltd            |   | Delaware         |
| Seer Technologies de Argentina      S.A        |   | Argentina        |
| Level 8 FSC, Inc                               |   | Barbados         |
| Level 8 Benelux    B.V                         |   | Netherlands      |
| Seer Technologies do Brasil      Ltd.          |   | Brazil           |
| Level 8 Canada,    Inc                         |   | Canada           |
| Level 8 Europe (Deutschland)      GmbH         |   | Germany          |
| Level 8 Ireland      Limited                   |   | Ireland          |
| Level 8 Systems Nordic      AB                 |   | Sweden           |
| Seer Korea Co.,      Limited                   |   | South      Korea |
| Seer Technologies Singapore PTY,      Limited  |   | Singapore        |
| Seer Technologies Hong Kong      Limited       |   | Hong      Kong   |
|                                           |   |             |
| 3020126      Canada, Inc. (fka Bizware)        |   | Canada           |

----
August 23, 2016

JUDGMENT

The Fourteenth Court of Appeals

CARLOS GALLEGOS-PIEDRA, Appellant

NO. 14-14-01027-CR V.

THE STATE OF TEXAS, Appellee

________________________________

This cause was heard on the transcript of the record of the court below. 

Having considered the record, this Court holds that there was no error in the 

judgment. The Court orders the judgment AFFIRMED.

We further order appellant pay all costs expended in the appeal.

We further order this decision certified below for observance.
NOT FOR PUBLICATION

UNITED STATES COURT OF APPEALS

FOR THE NINTH CIRCUIT

UNITED STATES OF AMERICA,

Plaintiff

- Appellee,

v.

DARCY PASCHALL,

Defendant

- Appellant. No. 16

- 50502

D.C. No. 3:05

- cr

- 00200

- BEN

MEMORANDUM *

Appeal from the United States District Court

for the Southern District of California

Roger T. Benitez, District Judge, Presiding

Submitted June 26, 2017 **

Before: PAEZ, BEA, and MURGUIA, Circuit Judges.

Darcy Paschall appeals from the district court ’s judgment and challenges the

six

- month custodial sentence and 51

- month term of supervision imposed upon

revocation of supervised release. We have jurisdiction under 28 U.S.C. § 1291,

and we affirm.

* This disposition is not appropriate for publication and is not precedent

except as provided by Ninth Circuit Rule 36

- 3.

** The panel unanimously concludes this case is suitable for decision

without oral argument. See Fed. R. App. P. 34(a)(2). 

# FILED

JUL 3 2017

MOLLY C. DWYER, CLER K

U.S. COURT OF APPEAL S2 16

- 50502

Paschall contends that the district court procedural ly erred by failing to

respond to her nonfrivolous argument in favor of leniency. We review for plain

error, see United States v. Valencia

- Barragan , 608 F.3d 1103, 1108 (9th Cir.

2010), and conclude that there was none. The record reflects that the distr ict court

considered Paschall’s argument and adequately explained its reasons for imposing

the sentence selected. See Rita v. United States

, 551 U.S. 338, 358

- 59 (2007).

Paschall also contends that the 51

- month term of supervised release is

substantively unreasonable in light of the district court’s willingness to terminate

supervision in two years if Paschall remains violation

- free

. The district court did

not abuse its discretio n. See Gall v. United States , 552 U.S. 38, 51 (2007). The

term of supervised release is substantively reason able in light of the 18 U.S.C.

§ 3583(e) sentencing factors and the totality of the circumstances, including

Paschall’s history of drug and alcoho l abuse

. See Gall , 552 U.S. at 51.

AFFIRMED.
Exhibit 14.1
  CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
  We consent to the incorporation by reference in the Registration Statements on Form S-8 (File Nos. 333-102288 and 333-92491) pertaining to the Employee Stock Option plans of Ellomay Capital Ltd. (“the Company”) and Forms F-3 (File Nos. 333-144171, 333-115826, 333-114428, 333-47842 and 333-92493) of the Company and in the related Prospectuses of our report dated March 10, 2010, with respect to the consolidated financial statements of Ellomay Capital Ltd. and its subsidiaries included in this Annual Report on Form 20-F for the year ended December 31, 2009.
  /s/ Kost Forer Gabbay & Kasierer
KOST FORER GABBAY & KASIERER

A Member of Ernst & Young Global
 
 Tel Aviv, Israel
 March 10, 2010
Kapag nagsimulang yumanig dahil sa lindol . . .

Bumaba, Magkubli, at Humawak.

FEMA 529T Tagalog 9/2005

Magkubli sa ilalim ng matibay na desk o mesa, humawak sa paa ng 

desk o mesa upang ang desk o mesa ay manatiling nasa ibabaw mo, 

at panatilihing nakababa ang iyong ulo hanggang tumigil ang pagyanig.

FEMA
§ 210.1 Status of current good manufacturing practice regulations. Cross Reference
Link to an amendment published at 89 FR 51769 , June 18, 2024.
( a ) The regulations set forth in this part and in parts 211, 225, and 226 of this chapter contain the minimum current good manufacturing practice for methods to be used in, and the facilities or controls to be used for, the manufacture, processing, packing, or holding of a drug to assure that such drug meets the requirements of the act as to safety, and has the identity and strength and meets the quality and purity characteristics that it purports or is represented to possess.
( b ) The failure to comply with any regulation set forth in this part and in parts 211, 225, and 226 of this chapter in the manufacture, processing, packing, or holding of a drug shall render such drug to be adulterated under section 501(a)(2)(B) of the act and such drug, as well as the person who is responsible for the failure to comply, shall be subject to regulatory action.
( c ) Owners and operators of establishments engaged in the recovery, donor screening, testing (including donor testing), processing, storage, labeling, packaging, or distribution of human cells, tissues, and cellular and tissue-based products (HCT/Ps), as defined in § 1271.3(d) of this chapter, that are drugs (subject to review under an application submitted under section 505 of the act or under a biological product license application under section 351 of the Public Health Service Act), are subject to the donor-eligibility and applicable current good tissue practice procedures set forth in part 1271 subparts C and D of this chapter, in addition to the regulations in this part and in parts 211, 225, and 226 of this chapter. Failure to comply with any applicable regulation set forth in this part, in parts 211, 225, and 226 of this chapter, in part 1271 subpart C of this chapter, or in part 1271 subpart D of this chapter with respect to the manufacture, processing, packing or holding of a drug, renders an HCT/P adulterated under section 501(a)(2)(B) of the act. Such HCT/P, as well as the person who is responsible for the failure to comply, is subject to regulatory action.
[43 FR 45076, Sept. 29, 1978, as amended at 69 FR 29828, May 25, 2004; 74 FR 65431, Dec. 10, 2009]
### Geology and promising areas for ground-water development in the Hualapai Indian Reservation, Arizona

By: F. R. Twenter

                            https://doi.org/10.3133/wsp1576A

#### Links

-                                                                                                                             Document:                                                                                                                                                                                                                                                  **Report**                                                                                                     (pdf)                                                                                                                                     
- Plate:  **Plate 1**                            (pdf)
- Download citation as:  RIS                         |                         Dublin                            Core

#### Abstract

Part or all of this report is presented in Portable Document Format                        (PDF). For best results viewing and printing PDF documents, it is recommended that you download                        the documents to your computer and open them with Adobe Reader. PDF documents opened from your                        browser may not display or print as intended. Download the latest version of Adobe Reader, free of charge. More information                        about viewing, downloading, and printing report files can be found at the common download problems FAQ.
§ 50.52 Clinical investigations involving greater than minimal risk but presenting the prospect of direct benefit to individual subjects. Any clinical investigation within the scope described in §§ 50.1 and 56.101 of this chapter in which more than minimal risk to children is presented by an intervention or procedure that holds out the prospect of direct benefit for the individual subject, or by a monitoring procedure that is likely to contribute to the subject's well-being, may involve children as subjects only if the IRB finds that: ( a ) The risk is justified by the anticipated benefit to the subjects;
( b ) The relation of the anticipated benefit to the risk is at least as favorable to the subjects as that presented by available alternative approaches; and
( c ) Adequate provisions are made for soliciting the assent of the children and permission of their parents or guardians as set forth in § 50.55.
[66 FR 20598, Apr. 24, 2001, as amended at 78 FR 12951, Feb. 26, 2013]
<PAGE>

                                                                   Exhibit 23.4


                       CONSENT OF INDEPENDENT AUDITORS


We consent to the reference to our firm under the caption "Experts" and to
the incorporation by reference of our report dated April 21, 1999 of Nur
Macroprinter Ltd. in its Registration Statement on Form S-8 filed with the
Securities and Exchange Commission and pertaining for the registration of
2,950,000 Ordinary Shares of Nur Macroprinters Ltd. issuable upon exercise of
options available for grant under its 1995 Flexible Stock Incentive Plan,
1997 Stock Option Plan and 1998 Non-Employee Director Share Option Plan.

Kost, Germany                               /s/ Willy Knyrim
November 30, 1999                           ----------------------------------
                                            Willy Knyrim


                                            DIPLOM-FINANCIALIST
                                                WILLY KNYRIM
                                      WIRTSCHAFTSPRUFER-STEUERBERATUR
                                      HUMBOLDTSTR, 37  34117 KASSEL
                                      Tel. (0561) 709 69.0  Fax (0561) 10 25 73
### Geology, hydrology, and chemical character of ground waters in the Torrance-Santa Monica area, California

By: J. F. PolandA. A. GarrettAllen Sinnott

                            https://doi.org/10.3133/wsp1461

#### Links

-                                                                                                                             Document:                                                                                                                                                                                                                                                  **Report**                                                                                                     (pdf)                                                                                                                                     
- Plates:                               - **Plate 1**                            (pdf)
  - **Plate 2**                            (pdf)
  - **Plate 3**                            (pdf)
  - **Plate 4**                            (pdf)
  - **Plate 5**                            (pdf)
  - **Plate 6**                            (pdf)
  - **Plate 7**                            (pdf)
  - **Plate 8**                            (pdf)
  - **Plate 9**                            (pdf)
  - **Plate 10**                            (pdf)
  - **Plate 11**                            (pdf)
  - **Plate 12**                            (pdf)
  - **Plate 13**                            (pdf)
  - **Plate 14**                            (pdf)
  - **Plate 15**                            (pdf)
  - **Plate 16**                            (pdf)
  - **Plate 17**                            (pdf)
  - **Plate 18**                            (pdf)
  - **Plate 19**                            (pdf)
  - **Plate 20**                            (pdf)
  - **Plate 21**                            (pdf) 
- NGMDB Index Page:  **National Geologic Map Database Index Page**                            (html)
- Download citation as:  RIS                         |                         Dublin                            Core

#### Abstract

No abstract available.

#### Study Area

Part or all of this report is presented in Portable Document Format                        (PDF). For best results viewing and printing PDF documents, it is recommended that you download                        the documents to your computer and open them with Adobe Reader. PDF documents opened from your                        browser may not display or print as intended. Download the latest version of Adobe Reader, free of charge. More information                        about viewing, downloading, and printing report files can be found at the common download problems FAQ.
§ 163.145 Mixed dairy product chocolates. ( a ) *Description.* Mixed dairy product chocolates are the foods that conform to the standard of identity, and are subject to the requirements for label declaration of ingredients for milk chocolate in § 163.130, except that: ( 1 ) The optional dairy ingredients for each of the foods are mixtures of two or more of the following: ( i ) Any dairy ingredients specified in § 163.130;
( ii ) Any dairy ingredients specified in § 163.135;
( iii ) Any dairy ingredients specified in § 163.140; or
( iv ) Malted milk; and
( 2 ) The finished mixed dairy product chocolates shall contain not less than 12 percent by weight of total milk solids derived from those dairy products referred to in paragraph (a)(1) of this section, exclusive of any added sweetener or other dairy-derived ingredient that is added beyond that amount that is normally present in the specified dairy product, and may contain less than 3.39 percent by weight of milkfat. The quantity of each component used in any such mixture is such that no component contributes less than one third of the weight of the total milk solids contributed by that component which is used in the largest proportion.
( b ) *Nomenclature.* The name of the food is “chocolate”, or “chocolate coating”, preceded by the designation of the type of milk ingredients used as prescribed in paragraph (a) of this section in order of predominance by weight, e.g., “milk and skim milk chocolate”.
<PAGE>

                         HANSEN, HUNTER & KIBBEE, P.C.
                          CERTIFIED PUBLIC ACCOUNTANTS
                           10260 S.W. Greenburg Road
Telephone                          Suite 1150                        Facsimile
(503) 244-2134                Portland, Oregon 97223            (503) 244-9754




                 CONSENT OF HANSEN, HUNTER & KIBBEE, P.C.



We consent to the incorporation by reference in this Amended Annual Report on 
Form 10-K/A, filed with the Securities and Exchange Commission by NHP 
Incorporated (NHP) of our reports dated, January 19, 1995, January 13, 1995, 
January 19, 1995, January 13, 1995, January 19, 1995, January 11, 1995, 
January 14, 1995, and January 13, 1995 with respect to the audits of Haines 
Associates Limited Partnership, King-Bell Associates, Monmouth Associates 
Limited Partnership, Pendleton Riverside Apartments Oreg., Ltd., Penn Hall 
Associates, Rodeo Drive Limited Partnership, South Mountain Terrace, Ltd., 
and Woodland Apartments, Oreg., Ltd. for the year ended December 31, 1994, 
and the incorporation by reference of such reports into NHP's Registration 
Statement on Form S-8 (No. 333-11933), NHP's Registration Statement on Form 
S-8 (No. 333-11863), NHP's Registration Statement on Form S-8 (333-11917), 
NHP's Registration Statement on Form S-8 (333-11857), and NHP's Registration 
Statement on Form S-8 (333-08137).

/s/ Hansen, Hunter & Kibbee, P.C.

   
Portland, Oregon
October 27, 1997
[No. 15619-2-III.

Division Three.

November 13, 1997.]

#### The State of Washington, *Respondent,*v. Eric B. Marks, *Appellant.*

Appeal from a judgment of the Superior Court for Spokane County, No. 96-8-00051-1, Richard J. Schroeder, J., entered March 26, 1996. *Affirmed in part, reversed in part*and *remanded*by unpublished opinion per Brown, J., concurred in by Kurtz, J., and Zagelow, J. Pro Tern.
§ 182.3795 Sodium sorbate. ( a ) *Product.* Sodium sorbate.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing practice.
[Federal Register Volume 75, Number 39 (Monday, March 1, 2010)]
[Notices]
[Pages 9231-9232]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4184]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Amended Notice of Meeting

    Notice is hereby given of a change in the meeting of the National 
Cancer Institute Special Emphasis Panel,

[[Page 9232]]

March 10, 2010, 8 a.m. to March 11, 2010, 6 p.m., Bethesda Marriott, 
5151 Pooks Hill Road, Bethesda, MD 20814 which was published in the 
Federal Register on February 1, 2010, 75 FR 5093.
    This FRN amends the dates of the meeting to May 10-11, 2010. The 
meeting is closed to the public.

    Dated: February 24, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-4184 Filed 2-26-10; 8:45 am]
BILLING CODE 4140-01-P